A Randomized, Controlled Clinical Trial Meant to Evaluate the Use of Glibenclamide on Acute aSAH.
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A randomized, open-labeled, blank-controlled and prospective trial meant to evaluate the use
of glibenclamide on acute aneurysmatic subarachnoid hemorrhage. Patients will allocated
randomly in two groups, one for 3.75 mg daily intake of glibenclamide for 7 days and another
as a blank contrast. General clinical data and late cognitive status will be accessed in both
groups.